Qiagen stock gains 2.32 percent as Q2 revenue beats estimates

Published on 10/06/2026 at 00:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock was last at USD 45.79 on October 5, 2026, with a USD 9.4 billion market cap. Q2 revenue reached USD 535.04 million against USD 527.50 million consensus.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0015002SN0) was last at USD 45.79 on the NYSE on October 5, 2026, up 2.32 percent, with a market capitalization of USD 9.4 billion. The latest earnings comparison remains a central reference point: Q2 2026 revenue reached USD 535.04 million against USD 527.50 million consensus, while EPS came in at USD 0.62 versus USD 0.60 expected, according to MarketBeat.

Q2 revenue clears estimates

The revenue result put QIAGEN USD 7.54 million above consensus, a measurable beat in a quarter when the company continued to balance research demand with molecular diagnostics growth. The same MarketBeat report said the previous-year quarter produced EPS of USD 0.60, putting the latest EPS USD 0.02 higher.

QIAGEN's fiscal 2026 guidance was set at USD 2.43 EPS in the cited earnings coverage, while the finance data show Q2 2026 operating margin at 25 percent and net income of USD 103.4 million. Those figures frame the stock's valuation discussion more clearly than the daily move alone.

FDA clearance broadens testing menu

On September 28, 2026, QIAGEN announced FDA clearance for the QIAstat-Dx BCID GN Plus AMR Panel. According to QIAGEN, the panel identifies 13 gram-negative pathogens and 18 antimicrobial resistance markers.

Together with the existing gram-positive and fungal panel, the US QIAstat-Dx bloodstream infection portfolio covers 33 pathogen targets and 28 resistance markers. The commercial test will be whether broader menu coverage leads to higher instrument placements and recurring consumable use, a point also raised by Simply Wall St on October 5, 2026.

Analyst target stays below price

MarketBeat lists a Hold consensus from 14 analysts and an average price target of USD 43.51. Its coverage also cites JPMorgan's USD 50 target and Jefferies' USD 48 target, showing a spread of views around the current USD 45.79 NYSE price.

Qiagen stock stays below yearly high

Qiagen stock was last at USD 45.79 on the NYSE at 4:00 p.m. ET on October 5, 2026. The session range was USD 44.45 to USD 46.00, while the 52-week range stood at USD 32.53 to USD 57.82 and volume reached 3,054,221 shares.